抗血栓药的发展及替格瑞的早期研究.pptVIP

BRILIQUE: Does Not Require Hepatic Metabolism For Activation Reference Schomig A. 替格瑞洛 — is there need for a new player in the antiplatelet-therapy field? N Engl J Med. 2009;361:1108–1111. 替格瑞洛 is rapidly absorbed following oral administration[Husted 2009:B; EMEA Label:A] 替格瑞洛 is metabolized primarily via cytochrome P450 3A enzymes and has one known active metabolite, ARC124910XX, that is present in blood at approximately one-third of the concentration of the parent drug[Teng 2010:A; EMEA Label:B] Although this metabolite has potency in inhibiting the P2Y12 receptor equivalent to that of the p